ArticleOrthopedic reviews2016
Long-term Clinical Results after Iloprost Treatment for Bone Marrow Edema and Avascular Necrosis.
Article in Orthopedic reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Conservative Treatment in Avascular Necrosis of the Femoral Head: A Systematic Review.Medical sciences (Basel, Switzerland) · 2024Pooled it
- Evidence-Supported HBO Therapy in Femoral Head Necrosis: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021Pooled it
- [Update of the German S3 guideline on atraumatic femoral head necrosis in adults].Der Orthopade · 2018Guideline
- Iloprost therapy achieves good clinical and radiological short and mid-term outcomes in patients with idiopathic aseptic osteonecrosis of the knee joint also in ARCO level II.Archives of orthopaedic and trauma surgery · 2025Article
- ILOBONE: A phase I/IIa randomized controlled trial to assess the safety and feasibility of local iloprost therapy for enhancing proximal humerus fracture healing- a pilot study design.Journal of orthopaedic surgery and research · 2025Article
- Hip joint-preserving strategies for treating osteonecrosis of the femoral head: From nonoperative to operative procedures.Journal of orthopaedic translation · 2025Review
- Subchondral insufficiency fracture of the knee: progress in the pathogenesis and treatment.Frontiers in surgery · 2025Review
- A Comparative Analysis of Osteochondritis Dissecans and Avascular Necrosis: A Comprehensive Review.Journal of clinical medicine · 2024Review
- A Current Review in the Orthopedic Management of Osteonecrosis of the knee Secondary to Treatment of Pediatric Hematologic Malignancy.Orthopedic reviews · 2024Article
- The Role of Conservative Management in the Avascular Necrosis of the Femoral Head: A Review of Systematic Reviews.Indian journal of orthopaedics · 2023Review
- Trends in Surgical Treatment of Femoral Head Osteonecrosis in South Korea: An Analysis Using Nationwide Claims Database.Clinics in orthopedic surgery · 2022Article
- The Use of Iloprost in the Treatment of Bone Marrow Edema Syndrome of the Proximal Femur: A Review and Meta-Analysis.Journal of personalized medicine · 2022Review
- Avascular Necrosis of Femoral Head-Overview and Current State of the Art.International journal of environmental research and public health · 2022Review
- Treatment options for secondary osteonecrosis of the knee.Orthopedic reviews · 2022Article
- Avascular necrosis after femoral neck fracture in children and adolescents: poor prognosis and risk factors.International orthopaedics · 2021Article
- [Osteonecrosis].Der Orthopade · 2021Article
- Osteonecrosis of the Femoral Head: an Updated Review of ARCO on Pathogenesis, Staging and Treatment.Journal of Korean medical science · 2021Review
- Current Treatment Modalities for Osteonecrosis of Femoral Head in Mainland China: A Cross-Sectional Study.Orthopaedic surgery · 2020Article
- Article
- Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today?: A 5-Year Update.The Journal of bone and joint surgery. American volume · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatments of avascular osteonecrosis (AVN) include both conservative and surgical methods which are dependent on the stage and progression of the disease. The vasoactive-prostaglandin-analogue iloprost (PGI2) has been utilized in several areas of medicine and recently has been used for the treatment of AVN. A total of 108 patients with 136 osteonecrosis of different joints, etiology and severity were treated with iloprost. The mean follow-up was 49.71 months: range 15-96 months, and outcome measurements recorded regarding subjective complaints, visual analog scale (pain), function and survival. The outcome scores used include the Harris Hip Score, Knee Society score, Foot and Ankle Survey, visual analogue scale (VAS) and a separate questionnaire. The location and etiology of AVN in our study demonstrated the typical pattern. All of the observed side effects of the therapy were minor and completely reversible. Most of patients (74.8%) showed a significant improvement of subjective complaints and decrease in VAS pain scores after the treatment with iloprost. However, 20% of the treated joints with the stadium Association for Research on Osseous Circulation (ARCO) grade 2, 71% with ARCO 3 and 100% with ARCO 4 underwent subsequent total joint replacement. The medical treatment of bone marrow edema or avascular osteonecrosis by Iloprost provides an safe and effective alternative strategy in the management of AVN presenting in the early stages (ARCO 1 or 2). For more advanced stages (ARCO 3 or 4), surgical intervention should be prioritized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.